MELOXICAM - Generic Drug Details
✉ Email this page to a colleague
What are the generic drug sources for meloxicam and what is the scope of patent protection?
Meloxicam
is the generic ingredient in five branded drugs marketed by Lupin Ltd, Novitium Pharma, Iceutica Operations, Baudax, Avondale Pharms, Tersera, Aiping Pharm Inc, Anda Repository, Ascent Pharms Inc, Aurobindo Pharma, Chartwell Rx, Cipla, Corepharma, Cr Double Crane, Dr Reddys Labs Inc, Glenmark Pharms Ltd, Impax Labs Inc, Lupin Pharms, Mylan, Natco Pharma, Puracap Pharm, Roxane, Strides Pharma, Sun Pharm Inds Inc, Taro, Unichem, Yabao Pharm, Yung Shin Pharm, Zydus Pharms Usa, and Boehringer Ingelheim, and is included in thirty NDAs. There are eleven patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.Meloxicam has sixty-four patent family members in twenty-two countries.
There are twenty-two drug master file entries for meloxicam. Forty-seven suppliers are listed for this compound.
Summary for MELOXICAM
International Patents: | 64 |
US Patents: | 11 |
Tradenames: | 5 |
Applicants: | 30 |
NDAs: | 30 |
Drug Master File Entries: | 22 |
Finished Product Suppliers / Packagers: | 47 |
Raw Ingredient (Bulk) Api Vendors: | 145 |
Clinical Trials: | 93 |
Patent Applications: | 7,202 |
Drug Prices: | Drug price trends for MELOXICAM |
Drug Sales Revenues: | Drug sales revenues for MELOXICAM |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for MELOXICAM |
What excipients (inactive ingredients) are in MELOXICAM? | MELOXICAM excipients list |
DailyMed Link: | MELOXICAM at DailyMed |
Recent Clinical Trials for MELOXICAM
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
University of Miami | Phase 4 |
TriHealth Inc. | Phase 3 |
Baptist Health South Florida | Phase 4 |
Pharmacology for MELOXICAM
Drug Class | Nonsteroidal Anti-inflammatory Drug |
Mechanism of Action | Cyclooxygenase Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for MELOXICAM
US Patents and Regulatory Information for MELOXICAM
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Iceutica Operations | VIVLODEX | meloxicam | CAPSULE;ORAL | 207233-002 | Oct 22, 2015 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Lupin Pharms | MELOXICAM | meloxicam | TABLET;ORAL | 077944-002 | Jul 19, 2006 | AB | RX | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
Cr Double Crane | MELOXICAM | meloxicam | TABLET;ORAL | 078039-002 | Dec 14, 2006 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for MELOXICAM
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Baudax | ANJESO | meloxicam | SOLUTION;INTRAVENOUS | 210583-001 | Feb 20, 2020 | ⤷ Sign Up | ⤷ Sign Up |
Baudax | ANJESO | meloxicam | SOLUTION;INTRAVENOUS | 210583-001 | Feb 20, 2020 | ⤷ Sign Up | ⤷ Sign Up |
Baudax | ANJESO | meloxicam | SOLUTION;INTRAVENOUS | 210583-001 | Feb 20, 2020 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
EU/EMA Drug Approvals for MELOXICAM
Company | Drugname | Inn | Product Number / Indication | Status | Generic | Biosimilar | Orphan | Marketing Authorisation | Marketing Refusal |
---|---|---|---|---|---|---|---|---|---|
Norbrook Laboratories (Ireland) Limited | Loxicom | meloxicam | EMEA/V/C/000141 DogsAlleviation of inflammation and pain in both acute and chronic musculoskeletal disorders. To reduce postoperative pain and inflammation following orthopaedic and soft-tissue surgery.CatsAlleviation of inflammation and pain in chronic musculoskeletal disorders in cats. To reduce postoperative pain after ovariohysterectomy and minor soft-tissue surgery.CattleFor use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle. For use in diarrhoea in combination with oral rehydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle. For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.PigsFor use in noninfectious locomotor disorders to reduce the symptoms of lameness and inflammation. For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.HorsesFor use in the alleviation of inflammation and relief of pain in both acute and chronic musculoskeletal disorders.For the relief of pain associated with equine colic. |
Authorised | yes | no | no | 2009-02-10 | |
Le Vet Beheer B.V. | Novaquin | meloxicam | EMEA/V/C/003866 Alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders in horses. |
Authorised | no | no | no | 2015-09-08 | |
Le Vet Beheer B.V | Meloxidolor | meloxicam | EMEA/V/C/002590 DogsAlleviation of inflammation and pain in both acute and chronic musculoskeletal disorders.Reduction of postoperative pain and inflammation following orthopaedic and soft-tissue surgery.CatsReduction of postoperative pain after ovariohysterectomy and minor soft-tissue surgery.CattleFor use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs.For use in diarrhoea in combination with oral rehydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.PigsFor use in noninfectious locomotor disorders to reduce the symptoms of lameness and inflammation.For the relief of postoperative pain associated with minor soft-tissue surgery such as castration.For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.HorsesFor use in the alleviation of inflammation and relief of pain in both acute and chronic musculoskeletal disorders.For the relief of pain associated with equine colic. |
Authorised | yes | no | no | 2013-04-22 | |
>Company | >Drugname | >Inn | >Product Number / Indication | >Status | >Generic | >Biosimilar | >Orphan | >Marketing Authorisation | >Marketing Refusal |
International Patents for MELOXICAM
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
South Korea | 20200130334 | 멜록시캄의 일시 투여량을 정맥내 투여하는 방법 | ⤷ Sign Up |
Australia | 2010254180 | Reduction of flake-like aggregation in nanoparticulate active agent compositions | ⤷ Sign Up |
China | 111356453 | 术前及与其他药物组合静脉内施用美洛昔康的方法 (Methods of administering intravenous meloxicam pre-operatively and in combination with other drugs) | ⤷ Sign Up |
>Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.